CD44 and colorectal cancer: Wielenga et al. [36] reported that, in colorectal cancer, heparin sulfate-modified CD44 showed increased ability of binding to hepatocyte growth factor/scatter factor (HGF/SF), thus presenting HGF/SF to c-Met and leading to c-Met phosphorylation, and triggering the c-Met signal pathway to activate lymphocyte function-associated antigen-1 (LFA-1), therefore, affecting the biological activities of tumor cells, such as angiogenesis and cell motivation.